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ABSTRACT
Objective: To investigate the in vivo anticancer and immunostimulatory activity of dichloromethane (DCM) extract of flowers of Mimosa pudica and 
its isolated compound 11β hydroxy-3 methoxy 1,2 dehydro crinane.
Methods: The anticancer activity was performed on Ehrlich ascites carcinoma (EAC) cell line in Swiss albino mice. The activity was assessed by 
evaluating tumor volume, viable and nonviable tumor cell count, tumor weight, hematological, and histopathological parameters of EAC-bearing 
animals. The immunostimulatory activity was performed through carbon clearance, delayed type hypersensitivity (DTH), neutrophil adhesion and 
humoral antibody (HA) titer methods.
Results: At the dose of 500 and 1000 mg/kg/day p.o for the extracts and 2.5 mg/kg/day p.o. for the isolated compound, significantly decrease the 
tumor volume (3.46±0.135 ml, 2.25±0.153 ml, and 1.84±0.012), increased the life span (59.32%, 76.39%, and 82.43%) and significantly (p<0.05) 
decreased tumor weight as compared with control. Hematological profiles were found to be nearly normal level in extract treated mice compared 
with tumor bearing control mice. The immunostimulatory activity was also found to be effective in the above dosage regimen. The results revealed 
that animals treated with above doses show a significant increase in the rate of carbon clearance from blood, increase in HA titer value, increase in 
neutrophil adhesion and significant (p<0.05) increase in mean paw edema in DTH reactions in dose-dependent manner.
Conclusion: The results demonstrated that the extract is possessing dose-dependent anticancer activity and immunostimulatory activity attributed 
to the presence of crinane alkaloid.
Keywords: Humoral antibody titer, Ehrlich ascites carcinoma cell line, LD50, Delayed type hypersensitivity, Dichloromethane, Mimosa pudica.
INTRODUCTION
Cancer is the prominent cause of mortality worldwide, and most of the 
chemotherapeutic agents have been reported to exhibit severe toxicity 
to normal tissues, accompanied by undesirable huge side effects [1]. 
Moreover, most of these drugs are very expensive, mutagenic, and 
carcinogenic. Therefore, novel pharmaceutical agents that provide 
a more specific therapeutic regimen or increase the efficacy of 
conventional chemotherapy, without increasing toxicity toward 
normal cells, would clearly be of great clinical benefit. Increasing 
evidence suggests that immune responses are involved in the control 
of cancer and that the immune system can be manipulated in different 
ways to recognize and treat cancers [2]. Progress in immune-based 
strategies has introduced a new therapeutic avenue using a number of 
techniques destined to eliminate malignant cells [3]. Recently, cancer 
chemoprevention with ideas using foods and medicinal herbs has 
been regarded as one of the most visible fields for cancer control [4]. 
Most of the anti-tumor drugs currently used in chemotherapy are 
toxic to normal cells and cause toxicity for immune cells. Therefore, 
the identification of new anticancer drug with low side effects on the 
immune system or which boosts it has become an essential goal in 
many studies of immunopharmacology.
The Mimosa pudica Linn. (Fabaceae) invites the attention of the researchers 
worldwide for its traditional use in various parts of the world. In Assam 
part of India, it is known by the name “Lajukilata” and traditionally used 
as antitumor, stimulant, antioxidant and for wound healing activity. 
Phytoconstituents such as alkaloids, sterols, and tannins together with 
other compounds such as mimosine, mimosinic acid, and gallic acid were 
already reported from this plant [5]. Although some studies are reported 
on anticancer activity of leaves and aerial plant parts extracts of M. pudica 
but no studies were conducted with the flowering parts of the plants. This 
study was undertaken to explore the anticancer and immunostimulatory 
property of flowers of M. pudica Linn using some in vivo models.
EXPERIMENTAL
Plants material
Flower parts of M. pudica were collected from local areas of Guwahati, 
Assam, India in the month of January 2012. The plant material was 
authenticated by Dr. GC Sharma, Curator, Department of Botany, Gauhati 
University, Guwahati (voucher specimen no. 17777).
Preparation of the extracts
The collected plant parts were washed with water; shade dried in open 
air and pulverized using an electric grinder. About 200 g of M. pudica 
powder was packed into Soxhlet apparatus and subjected to successive 
extraction using petroleum ether, ethyl acetate, dichloromethane 
(DCM), and butanol as the solvent. The preliminary phytochemical 
and pharmacological screening shows a good result for DCM extract, 
therefore it is selected for further studies. The extract was filtered 
through Whatman filter paper No. 40, evaporated using vacuum rotary 
evaporator (Buchi) and heated on a water bath at 45±5°C and stored in 
vacuum desiccators for further use [6,7].
Isolation of compound
M. pudica flower DCM extracts were fractioned by column 
chromatography using silica gel 60-120 as stationary phase and 
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methanol–chloroform as mobile phase. The isolated compound was 
purified using preparative thin layer chromatography (TLC) techniques. 
The spot of the compound was scraped, collected, and then diluted with 
chloroform:methanol (7:3). The compound was obtained in the form of 
a crystal after filtration and evaporation. It was identified by ultraviolet, 
Fourier-transform infrared, nuclear magnetic resonance, and mass 
spectroscopic methods. The compound is identified as 11β hydroxy-3 
methoxy 1,2 dehydro crinane.
Drugs and chemicals
Extra immune tablets (Charak pharmaceuticals) and cyclophosphamide 
in the form of cycloxan-50 tablet (Biochem Pharmaceuticals) 
were locally purchased from the medicine store. Trypan blue was 
purchased from Hi media Laboratories Pvt. Ltd, Mumbai. Nylon fiber 
purchased from local market Guwahati, Assam, India. Methotrexate was 
obtained from IPCA Laboratories, Mumbai.
Animals
The study was conducted using Swiss albino mice weighing 20±5 g. 
They were obtained from the animal house of GIPS. The mice were 
grouped, housed in polycrylic cages and maintained under standard 
laboratory conditions (temperature 25±2°C) with light/dark cycle 
(12/12 hr). They were allowed free access to a standard dry pellet diet 
and water ad-libitum [8].
Acute toxicity study
The acute toxicity study was conducted as per the OECD guidelines 
425. Initially, the DCM extract was administered orally at a limit dose 
of 2000 mg/kg for the extract and 10 mg/kg for the isolated compound 
to single mice. The mice were observed closely for the first 4 hr and 
then periodically up to 24 hr for any toxic symptoms and mortality. 
After 24 hr same dose was administered to four more female rats. This 
study was approved by the Animal Ethics Committee of Girijananda 
Chowdhury Institute of Pharmaceutical Sciences, Guwahati, Assam 
(CPCSEA Regn. No.1372/C/10/CPCSEA. Study approval No-GIPS/
IAEC/07). The acute toxicity study was conducted for 24 hrs.
Anticancer activity of DCM extract of M. pudica
Experimental protocol
For this study, animals are divided into seven groups each containing six 
animals. All the animals expect the normal group received Ehrlich ascites 
carcinoma (EAC) cells 1×106 cells/mouse. Group I (normal) received 
0.9% normal saline orally, Group II (control) 0.9% normal saline orally, 
Group III treated with standard methotrexate at 2.5 mg/kg/day p.o, 
Group IV treated with 250 mg/kg/day p.o of DCM extract, Group V with 
500 mg/kg/day p.o of DCM extract, Group VI with 1000 mg/kg/day p.o 
of DCM extract, and Group VII treated with treated with 2.5 mg/kg/day 
p.o of isolated compound. All treatments were given for 9 days [9].
Determination of body weight and mean survival time (MST) of 
the DCM extract treated mice
The body weight and MST of each group consisting of six mice were 
noted. The antitumor efficacy of M. pudica was compared to that of 
methotrexate. The percentage increase life span (% ILS) of each mouse 
was calculated using the following equation:





Where T=number of days the treated animals survived and C=number 
of days control animals survived.
Determination of viable and nonviable cell count of the DCM 
extract treated mice
The viability and nonviability of the cells were checked for the above 
groups by trypan blue assay. The cells were stained with trypan blue 
(0.4% in normal saline) dye. On staining, the viable cells did not take 
the stain while the nonviable cells were stained blue and counted using 
Invitrogen Auto cell counter.
Determination of hematological parameters of the DCM extract 
treated mice
At the end of the experimental period, the next day after an overnight 
fasting, blood was withdrawn from the retro-orbital plexus and used 
for the estimation of hemoglobin (Hb) content, red blood cell (RBC) 
count and white blood cell (WBC) count using an automatic analyzer. 
Half of the animals from each group were sacrificed and checked for 
tumor volume.
Histopathological study of the DCM extract treated mice
A part of the dissected liver from sacrificed animals of all the groups 
was cleared off of the surrounding tissues and kept in 10% buffered 
neutral formalin, dehydrated in alcohol, and then embedded in paraffin. 
The paraffin blocks were sectioned at a size of 5 µm and stained with 
hematoxylin and eosin dye and observed under a light microscope for 
the array of hepatic cords radiating from the central vein and size of 
sinusoids.
Immunostimulatory activity of DCM extracts of M. pudica flower 
and its isolated compound
Experimental protocol
Mice were divided into seven groups, each containing six animals. 
Group I (control) was given 1% sodium carboxymethyl cellulose in 
water (0.3 ml/mouse) for 7 days, Group II was administered with 
2.5 mg/kg/day p.o of immunogen and marked as positive standard, 
Group III was negative standard administered with 2.5 mg/kg/day p.o 
of cyclophosphamide, and Groups IV-VI were administered with 250, 
500, and 1000 mg/kg/day p.o. dosage of DCM extracts for seven days. 
Group VII was administered with isolated compound at the dose of 
2.5 mg/kg/day p.o. At the end of seven days, mice of all the groups were 
studied for immunostimulatory activity [10].
In vivo carbon clearance test
At the end of 7 days, mice of all the groups were injected via the tail 
vein the carbon ink suspension (10 µl/g body weights). Blood samples 
were drawn (in EDTA solution 5 µl) from the retro-orbital vein at 
intervals of 0 and 15 minutes, a 25 µl sample was mixed with 0.1% 
sodium carbonate solution (2 ml), and their absorbance was measured 
at 660 nm. The carbon clearance was calculated using the equation: 
(Loge OD1−Loge OD2)/15, where OD1 and OD2 are the optical densities at 
0 and 15 minutes, respectively [11,12].
Humoral antibody (HA) titer test
The animals of all the groups were immunized by injecting 0.1 ml of 
sheep RBCs (SRBCs) suspension containing 1×108 cells intraperitoneally 
on day 0. Blood samples were collected in microcentrifuge tubes from 
an individual animal of all the groups by retro-orbital vein puncture on 
day 8. The blood samples were centrifuged, and serum was separated. 
Antibody levels were determined by the hemagglutination technique. 
Briefly, equal volumes of (50 µl) individual serum samples of each group 
were polled. To serial two-fold dilutions of pooled serum samples made 
in 50 µl volumes of RPMI-1640 in microtitration plates, 50 µl of 1% 
suspension of SRBC in RPMI-1640 was added. After mixing, the plates 
were incubated at 37°C for 1 hr and examined for hemagglutination 
under a microscope (button formation). The reciprocal of highest 
dilution, just before the button formation, was observed as the titer 
values of the test samples [13].
Delayed type hypersensitivity (DTH) test
The experiment of DTH was commenced after the HA titer model in 
the same animals. On day 8, the thickness of the right hind footpad 
was measured using vernier caliper. The mice were then challenged 
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by injection of 1×108 SRBCs in the right hind footpad. The footpad 
thickness was measured again after 24 hrs and 48 hrs of the challenge. 
The difference between the pre- and post-challenge footpad thickness 
expressed in mm was taken as a measure of DTH response [14,15].
Neutrophil adhesion test
The mice were pre-treated orally with vehicle or extracts for 14 days 
as above. At the end of treatment day 14, blood samples were collected 
from the retro-orbital plexus into heparinized vials and analyzed 
for differential leukocyte count (DLC). After the initial counts, blood 
samples were incubated with 80 mg nylon fibers/ml for 15 minutes 
at 37°C. The incubated blood samples were again analyzed for TLC 
and DLC, respectively, to give neutrophil index of blood samples. The 







Where NIu is the neutrophil index of untreated blood samples and NIt is 
the neutrophil index of treated blood samples [16,17].
Statistical analysis
Data analysis was performed using Graph Pad Prism software, and the 
data were expressed as a mean±standard error. The significance level 
of treatment effect was determined by one-way analysis of variance; 
p<0.05 was considered statistically significant.
RESULTS
Acute dose toxicity study
The DCM extract did not show any toxic reactions and mortality up 
to a dose of 2000 mg/kg for the extract and 10 mg/kg for the isolated 
compound. No changes in food consumption, water intake or behavior 
(tremors, convulsions, salivation, diarrhea, lethargy, sleep, and coma) were 
observed in the mice after dose administration. Hence, DCM 250 mg/kg, 
500 mg/kg, and 1000 mg/kg were taken as treatment dose for this study.
Anticancer activity of DCM extract of M. pudica
Administration of DCM extract at the doses of 500 mg/kg, 1000 mg/kg 
and isolated compound at 2.5 mg/kg significantly decreased the tumor 
volume and viable cell count and increases the nonviable cell count in 
dose treated mice when compared with control group (Table 1). Further, 
the MST was increased to 29.76 (% ILS=59.32%) for 500 mg/kg group, 
35.36 (% ILS=76.39%) for 1000 mg/kg group, and 36.74 (82.43) for the 
isolated compound on oral administration. After treatment with DCM 
extract at the doses, 500 mg/kg, 1000 mg/kg and isolated compound at 
2.5 mg/kg in EAC-bearing mice significantly increased the RBC count and 
Hb content (p<0.05) and significantly reduced the WBC count as compared 
with the EAC control group (Table 2). In EAC treated mice liver section 
showed dilation and congestion in the central and portal veins of the liver 
with respect to control mice (Fig. 1a and b). The microscopic examination 
of liver reveled thickening in hepatic capsule with inflammatory and 
pigmented cells as well as with diffuse Kupffer cells. The treatment with 
DCM extracts has reduced most of the pathological alteration observed 
in EAC control group. The liver section showed few inflammatory cells 
infiltration in the hepatic parenchymal associated with slight congestion 
in the central vein (Fig. 1d and e). The treatment group of DCM 1000 and 
isolated compound shows a normal array of hepatic cord radiating from 
the central vein and smaller sinusoids (Fig. 1f and g). The anticancer 
activity of the M. pudica at the concentration of DCM 500 and DCM 1000 
was found to be equipotent with the standard drug methotrexate at 
2.5 mg/kg concentration (Fig. 1c).
Immunostimulatory activity of DCM extracts of M. pudica flower 
and its isolated compound
The results revealed that animals treated with doses of the extracts 
at 500 and 1000 mg/kg show much increase rate of carbon clearance 
(Fig. 2) from blood (0.03986±0.0017 and 0.04328±0.0035, respectively). 
The isolated compound also shows increase in carbon clearance rate 
(0.05462±0.0043). Treatment of mice with DCM extracts of the plant 
at 250-1000 mg/kg doses and isolated compound at 2.5 mg/kg doses 
shows much increase in HA titer value as evident from hemagglutination 
after incubation of serum with SRBCs (Fig. 3). In DTH response test the 
extract showed statistically significant increase in mean paw edema 
in dose-dependent manner (0.37±0.04 for 24 hrs, and 0.28±0.02 for 
48 hrs with 1000 mg/kg, 0.34±0.05 for 24 hrs and 0.25±0.03 for 48 hrs 
with 500 mg/kg and 0.28±0.03 for 24 hrs, and 0.27±0.03 for 48 hrs with 
250 mg/kg doses of DCM extract of M. pudica) in mice, as compared 
with (0.42±0.21 for 24 hrs and 0.34±0.08 for 48 hrs, respectively) the 
standard drug immunogen at a concentration of 2.5 mg/kg (Table 3). 
Table 1: Effect of DCM extract of M. pudica on tumor weight, MST and life span of EAC-bearing mice
S. No. Treatment Tumor weight (g) MST (days) % increase in life span
1. EAC control 7.29±0.256 16.44±0.016
2. Methotrexate 2.5 mg/kg 2.46±0.087 38.98±0.032 87.32±1.265
3. DCM 250 5.76±0.018 20.32±0.127 36.98±0.986
4. DCM 500 4.91±0.023 29.76±0.098 59.32±0.098
5. DCM 1000 2.98±0.189* 35.36±0.012* 76.39±0.786*
6. Isolated compound 2.5 2.93±0.134* 36.74±0.122 82.43±0.124
Values are mean±SEM of 3 replicates. *p<0.05. DCM 250: Dichloromethane extract of M. pudica at 250 mg/kg, DCM 500: Dichloromethane extract of M. pudica at 
500 mg/kg, DCM 1000: Dichloromethane extract of M. pudica at 1000 mg/kg. SEM: Standard error of mean, MST: Mean survival time, EAC: Ehrlich ascites carcinoma, 
M. pudica: Mimosa pudica
Table 2: Effect of DCM extracts of M. pudica on hematological parameters of EAC treated mice
S. No. Treatment RBC count  
(1×106 cells/mm3)
WBC count  
(1×103 cells/mm3)
Viable cells  
(1×107 cells/mm3)






1. EAC control 2.84±0.072 26.31±0.237 7.52±0.172 1.52±0.012 4.37±0.237 8.23±0.014
2. Methotrexate 2.5 mg/kg 8.76±0.078 12.98±1.012 2.60±0.043 5.32±0.98 13.27±0.086 1.94±0.139
3. DCM 250 mg/kg 3.18±0.059 25.73±0.068 5.98±0.217 2.74±1.243 6.79±0.165 5.14±0.025
4. DCM 500 mg/kg 6.14±0.019* 15.72±0.142 3.74±1.078 4.67±0.189 8.63±0.156 3.46±0.135
5. DCM 1000 mg/kg 7.46±0.139* 13.47±0.037* 2.36±0.062* 6.74±0.072* 11.97±0.337 2.25±0.153*
6. Isolated compound 
2.5 mg/kg
8.23±0.136* 11.92±0.145* 2.25±0.128* 4.93±0.0125 12.32±0.271 1.84±0.012*
Values are mean±SEM of 3 replicates. *p<0.05. DCM 250: Dichloromethane extract of M. pudica at 250 mg/kg, DCM 500: Dichloromethane extract of M. pudica at 
500 mg/kg, DCM 1000: Dichloromethane extract of M. pudica at 1000 mg/kg. SEM: Standard error of mean, EAC: Ehrlich ascites carcinoma, M. pudica: Mimosa pudica, 
RBC: Red blood cell, WBC: White blood cell
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Isolated compound also exhibits good response for DTH response 
(0.39±0.15 for 24 hrs and 0.32±0.12 for 48 hrs). In neutrophil adhesion 
test, the incubation of blood with nylon fibers produced a decrease 
in the neutrophil counts due to adhesion of neutrophils to the fibers. All 
the doses of DCM extract of M. pudica showed a significant increase in 
the neutrophil adhesion when compared to standard drug immunogen 
and isolated compound (Fig. 4).
The results thus depict a good anticancer and immunostimulatory 
activity of DCM extracts of flower of M. pudica and its isolated compound 
11β hydroxy-3 methoxy 1,2 dehydro crinane.
DISCUSSION
Many plant products used in traditional medicine as anticancer 
agents have been reported to have immunostimulatory activities. 
The immunotherapeutic properties of these plants extracts initiate 
the enhancement of anticancer response by inhibiting secretions of 
inhibitory cytokines and recruitment of immune cells in the tumor 
site. In this study, we found that DCM extracts of M. pudica significantly 
shows both anticancer and immunostimulatory activity in experimental 
mice which gives a strong evidence for the traditional usage of 
immunostimulatory anticancer drugs.
Table 3: Effect of DCM extract of M. pudica and isolated compound 2 on delayed type hypersensitivity
S. No. Treatment Dose (mg/kg) Mean of right footpad thickness (mm)
24 hrs 48 hrs
1. Control - 0.16±0.05 0.16±0.02
2. Sensitized control - 0.26±0.12 0.23±0.02**
3. + Std 2.5 0.42±0.09* 0.34±0.08
4. − Std 2.5 0.17±0.07 0.17±0.04*
5. DCM 250 mg/kg 250 0.28±0.03 0.27±0.03
6. DCM 500 mg/kg 500 0.34±0.05** 0.25±0.03**
7. DCM 1000 mg/kg 1000 0.37±0.04* 0.28±0.02*
8. Isolated compound 2.5 mg/kg 1000 0.39±0.15* 0.32±0.12*
All values are expressed as mean±SEM of three observations. *p<0.05, **p<0.01 comparing with the control. DCM 250: Dichloromethane extract of M. pudica at 
250 mg/kg, DCM 500: Dichloromethane extract of M. pudica at 500 mg/kg, DCM 1000: Dichloromethane extract of M. pudica at 1000 mg/kg. SEM: Standard error of 
mean, M. pudica: Mimosa pudica
Fig. 2: Results for carbon clearance test (absorbance) for 
dichloromethane extracts of Mimosa pudica and isolated compound. 
DCM 250: Dichloromethane extract of M. pudica at 250 mg/kg, 
DCM 500: Dichloromethane extract of M. pudica at 500 mg/kg, DCM 
1000: Dichloromethane extract of M. pudica at 1000 mg/kg
Fig. 1: Histopathological interpretation of dichloromethane (DCM) extracts and compound 2 from Mimosa pudica flower on the liver 
section of Swiss albino mice. (a) Control: Normal nucleus, hepatocytes are radiating outward from a central vein in the center. (b) Ehrlich 
ascites carcinoma control: Cellular inflammatory infiltration, nuclear hypertrophy, debris in the central vein, hemorrhages and wide 
sinusoids. (c) Standard: Cytoplasmic degeneration has been reduced, mild cellular inflammatory infiltration and nuclei of hepatic cells 
are better. (d) DCM 250: Cellular inflammatory infiltration, moderate nuclear hypertrophy, little debris in the central vein and wide 
sinusoids. (e) DCM 500: Cytoplasmic degeneration has nearly reduced mild cellular inflammatory infiltration and normal array of hepatic 
cords radiating from the central vein. (f) DCM 1000: Relatively small sinusoids, cellular hemorrhage is not very prominent, no debris 
in the central vein and mild cellular inflammatory infiltration. (g) Compound 2. Very small sinusoids, cellular hemorrhage is not very 
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The results from the acute dose toxicity study reveals that the animals 
treated with the DCM extract at a higher dose of 2000 mg/kg and isolated 
compound at 2.5 mg/kg, did not produce any significant toxicity signs, 
behavioral changes, body weight changes, or macroscopic findings 
during the observational period. Hence, the LD50 of DCM extract of 
M. pudica and isolated compound should be more than 2000 mg/kg and 
10 mg/kg, respectively.
This study indicated that the DCM extracts of flowers of M. pudica 
have significantly enhanced the erythrocyte count and Hb level 
when compared to that of EAC control indicating the apoptosis-
inducing capacity of the extract. Viable cell count was decreased, 
and nonviable cell count was increased in intraperitoneal fluid by 
the plant extracts in a dose-dependent manner. This indicated a 
toxic effect on these cells that resulted in cell death. It signifies that 
the drug was absorbed directly by the EAC cells in the peritoneal 
cavity and causes the lysis of the EAC cell by the direct cytotoxic 
mechanism. The antitumor activity of the plant extracts at 500 and 
1000 mg/kg and isolated compound at 2.5 mg/kg body weight dose 
was effective as the standard drug methotrexate suggesting its potent 
activity as an antitumor agent. The histopathological examination of 
the liver section revels that the extract treated mice group shows 
normal array of hepatic cord radiating from the central vein and 
smaller sinusoids in a dose-dependent manner which signifies the 
replacement of cancerous cells with normal cells (Bhadoriyal and 
Mandoriya, 2012).
Further, the study reveals that the extracts (250-1000 mg/kg) and 
isolated compound (2.5 mg/kg) evoked a significant increase in 
percent neutrophil adhesion and rate of carbon clearance. This may 
potentially help in increasing immunity of body against microbial 
infections by upregulation of β2 integrins present on the surface of 
the neutrophil. The high values of hemagglutinating antibody titer 
obtained in the case of the plant’s extracts and isolated compound 
have indicated that immunostimulation was achieved through 
humoral immunity. The increase in DTH reaction in mice in response 
to SRBC antigen revealed significant paw edema (p<0.05) in the dose-
dependent manner (250-1000 mg/kg) for the plant’s extracts and 
isolated compound at 2.5 mg/kg. In this study, we found that DCM 
extracts and isolated compound modulate both cellular and humoral 
immunity in experimental mice. Thus, the DCM extract of flowers of 
M. pudica and isolated compound 11β hydroxy-3 methoxy 1,2 dehydro 
crinane can be a promising anticancer agent with immunostimulant 
property.
CONCLUSION
In this work, it is observed that anticancer activity of M. pudica 
Linn. (Fabaceae) is due to the stimulation of macrophages which 
are the important cells for the immune system. Thus, this study can 
further be proceed for a better understanding of anticancer and 
immunostimulatory mechanism of M. pudica which can be a boon for 
the human society.
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DCM 500: Dichloromethane extract of M. pudica at 500 mg/kg, 
DCM 1000: Dichloromethane extract of M. pudica at 1000 mg/kg
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